Literature DB >> 1969151

Quazepam: hypnotic efficacy and side effects.

A Kales1.   

Abstract

Quazepam is a benzodiazepine hypnotic that can be useful in the adjunctive pharmacologic treatment of insomnia. It is slowly eliminated due to the long elimination half-lives of the parent compound and its two active metabolites, 2-oxoquazepam and N-desalkyl-2-oxoquazepam. This drug is recommended in doses of 15 mg for adults and 7.5 mg for geriatric patients. Sleep laboratory studies and clinical trials have shown that the 15 mg dose is quite efficacious for inducing and maintaining sleep not only with initial and short-term use but also with continued use. The 7.5 mg dose which has been studied less extensively has also been shown to be effective for inducing and maintaining sleep. There is considerable evidence of carryover effectiveness both during drug administration and after withdrawal. Thus, rebound phenomena are not observed during administration (early morning insomnia and daytime anxiety) and after withdrawal (rebound insomnia). Furthermore, certain behavioral side effects that have occurred with certain benzodiazepines (triazolam) have not been reported with quazepam. The only notable side effect seen with quazepam is a variable degree of daytime sedation, which can be minimized by intermittent use of the 15 mg dose when necessary and use of the 7.5 mg dose in the elderly. In comparison to triazolam and temazepam, quazepam is more effective with short-term use, and with continued use it maintains its efficacy in contrast to both of these drugs which show rapid development of tolerance. Most important, quazepam lacks the frequent and severe side effects increasingly reported with triazolam use or following its withdrawal.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1969151

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  7 in total

1.  Time effects of food intake on the pharmacokinetics and pharmacodynamics of quazepam.

Authors:  Norio Yasui-Furukori; Takenori Takahata; Tsuyoshi Kondo; Kazuo Mihara; Sunao Kaneko; Tomonori Tateishi
Journal:  Br J Clin Pharmacol       Date:  2003-04       Impact factor: 4.335

Review 2.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

3.  Intramuscular Toradol, gastrointestinal bleeding, and peptic ulcer perforation: a case report.

Authors:  T L Yarboro
Journal:  J Natl Med Assoc       Date:  1995-03       Impact factor: 1.798

Review 4.  Drug treatment of patients with insomnia and excessive daytime sleepiness: pharmacokinetic considerations.

Authors:  S Nishino; E Mignot
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

Review 5.  Rebound insomnia and newer hypnotics.

Authors:  M Lader
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

6.  Drug interaction between St John's Wort and quazepam.

Authors:  Atsuhiro Kawaguchi; Masami Ohmori; Shu-Ichi Tsuruoka; Kenta Nishiki; Kenichi Harada; Isamu Miyamori; Ryo-Ichi Yano; Toshiaki Nakamura; Mikio Masada; Akio Fujimura
Journal:  Br J Clin Pharmacol       Date:  2004-10       Impact factor: 4.335

Review 7.  Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations.

Authors:  Francesca Borrelli; Angelo A Izzo
Journal:  AAPS J       Date:  2009-10-27       Impact factor: 4.009

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.